<Blinded Review: TIME_ANON_0852>
**Composite Score:** 3.2 / 10.0 (Rigor: 0.8/3.5 | Claims: 0.8/2.5 | Biology: 0.8/2.0 | Reproducibility: 0.8/2.0)
**Bias Category:** Statistical/Design
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Clinical/Observational
OVERALL_SCORE: 3.2/10
VERDICT: FAILED
ESTIMATED_DECADE: 2020s

---

### 1. Executive Summary (SUMMARY)
This hospital-based cross-sectional case-control study evaluates the association of the paraoxonase-1 (*PON1*) Q192R (rs662, c.575A>G) polymorphism and routine serum lipid parameters with coronary artery disease (CAD) in 165 patients (106 CAD cases undergoing PCI and 59 non-CAD chest-pain controls) from North Macedonia. Using a commercial TaqMan genotyping assay, the authors compare genotype distributions between CAD and non-CAD groups ($\chi^2 = 3.4508, p = 0.0632$) and between a post-hoc "stenting" subgroup and non-CAD controls ($\chi^2 = 4.1432, p = 0.0418$). The manuscript exhibits severe methodological, mathematical, and genetic flaws: the genotype distribution violates Hardy-Weinberg equilibrium at $p < 10^{-11}$ (indicating massive TaqMan allelic discrimination clustering failure), the reported 95% confidence intervals for the odds ratios in the Abstract and Tables 4–5 are mathematically impossible, sample sizes across Tables 1, 3, 4, and 5 contradict one another, and despite stating in the Introduction that they "analyse the relationship between enzyme activity, genotypic variants of the rs662 polymorphism and the risk of coronary artery disease," PON1 enzymatic activity was never measured.

### 2. Methodological & Statistical Audit (WEAKNESSES & METHODOLOGICAL AUDIT)
* **Catastrophic Violation of Hardy-Weinberg Equilibrium (Genotyping Artifact):** In Table 1, the reported *PON1* Q192R genotype counts across the cohort ($N = 164$ genotyped) are:
  * **CAD ($n = 105$):** $\text{QQ} = 22$, $\text{QR} = 81$, $\text{RR} = 2$ (77.1% heterozygotes!)
  * **non-CAD ($n = 59$):** $\text{QQ} = 20$, $\text{QR} = 39$, $\text{RR} = 0$ (66.1% heterozygotes!)
  * **Total ($N = 164$):** $\text{QQ} = 42$, $\text{QR} = 120$, $\text{RR} = 2$.
  Under these counts, the allele frequencies are $p(\text{Q}) = (2 \times 42 + 120)/328 = 0.622$ and $q(\text{R}) = (120 + 2 \times 2)/328 = 0.378$. The expected HWE genotype counts in $N = 164$ are $\text{E(QQ)} = 63.4$, $\text{E(QR)} = 77.1$, and $\text{E(RR)} = 23.4$. Observing $120$ heterozygotes and only $2$ RR homozygotes yields $\chi^2_{\text{HWE}} = 50.7$ ($p = 1.08 \times 10^{-12}$; in controls alone, $\chi^2_{\text{HWE}} = 14.5, p = 0.00014$). In European/Balkan populations, the *PON1* 192R allele frequency is $\sim 0.25\text{--}0.30$ with $\sim 7\text{--}10\%$ RR homozygotes. An extreme heterozygote excess ($73.2\%$ QR) paired with near-total absence of RR homozygotes is a classic technical artifact of failed TaqMan cluster separation (e.g., cross-talk between VIC and FAM channels or running Applied Biosystems TaqMan probes analyzed on mismatched "Thermo Scientific PikoReal PCR 2 Allelic Discrimination Software" without proper ROX/dye calibration).
* **Mathematically Impossible 95% Confidence Intervals in Abstract, Results, and Tables 4 & 5:**
  1. In Table 4 ($\text{QQ}$: $20$ non-CAD vs. $22$ CAD; $\text{QR+RR}$: $39$ non-CAD vs. $83$ CAD), the point Odds Ratio is $\text{OR} = (20 \times 83)/(22 \times 39) = 1.935$ (or its reciprocal $0.517$, reported as $0.511$). The true 95% Wald confidence interval for $\text{OR} = 0.517$ is $[0.253, 1.055]$ (which crosses $1.0$, consistent with $p = 0.0632$). However, the authors report `OR = 0.511 [95% CI: 0.25–0.595]`! An upper 95% CI bound of $0.595$ for a point estimate of $0.511$ is both asymmetric on the log scale ($\ln(0.511/0.25) = 0.715$ vs. $\ln(0.595/0.511) = 0.152$) and falsely excludes $1.0$ even though $p = 0.0632$. Clearly, $1.0595$ was miscopied or miscalculated as $0.595$.
  2. Exactly the same error occurs in Table 5 ($\text{QQ}$: $20$ vs. $17$; $\text{QR+RR}$: $39$ vs. $72$), where $\text{OR} = (17 \times 39)/(20 \times 72) = 0.460$, the true 95% CI is $[0.216, 0.980]$, and the authors report `0.461 [95% CI: 0.216–0.589]` (truncating $0.98$ to $0.589$).
* **Internal Contradictions in Sample Sizes Across Tables 1, 2, 3, 4, and 5:**
  1. **Stenting Subgroup Count Contradiction:** In Table 1 (line 76), the number of CAD patients with `Stent` is $36$ (and `Restenosis` is $46$, summing to $82$). Yet in Table 5 (`non-CAD vs. stenting`), the `Stenting` column contains $17\ (\text{QQ}) + 72\ (\text{QR+RR}) = 89$ patients! Where did 89 stenting patients come from when Table 1 states only 36 had a stent?
  2. **QQ Genotype Count Contradiction:** In Table 1 and Table 4, the total number of $\text{QQ}$ individuals is $22 + 20 = 42$ (and total genotyped is $42 + 120 + 2 = 164$, missing 1 CAD patient). Yet in Table 3 (lines 132–133), the sample size for $\text{QQ/QR/QR+RR}$ is listed as `45/120/122` (total $45 + 122 = 167$ patients, exceeding the entire study size of $165$!).
  3. **Smoking Prevalence Contradiction:** Line 65 states *"70% of the participants were smokers."* Yet in Table 1 (line 75), `Smoking` is listed as $31\ (70\%)$ in CAD and $13\ (30\%)$ in non-CAD—meaning only $31 + 13 = 44$ out of $165$ participants ($26.7\%$) were smokers, and the authors confused the row percentage ($31/44 = 70.5\%$ of smokers were in the CAD group) with the overall cohort smoking prevalence!
  4. **Gender Matching Contradiction:** Line 52 states that the control group was *"matched for gender and age"*, yet Table 1 shows that CAD cases are $75.5\%$ male ($80/106$) and $64.72$ years old, whereas controls are only $52.5\%$ male ($31/59$, $\chi^2 = 9.07, p = 0.0026$) and $61.83$ years old ($p = 0.0428$, Table 2). Because HDL and ApoA1 are strongly sex-dimorphic (higher in females) and statin dose is significantly higher in CAD cases ($31.42$ vs. $21.95\text{ mg/day}, p = 0.0013$), unadjusted one-way ANOVAs comparing HDL and ApoA1 between CAD and non-CAD (Table 2) are heavily confounded by sex and statin therapy.
  5. **Total Cholesterol ANOVA $p$-value Error (Table 2):** In Table 2 (line 124), `CAD` mean is $3.7$, `nonCAD` mean is $3.45$, yet `All patients` mean is listed as $3.7$ (impossible weighted average of $3.7$ and $3.45$) and the ANOVA $p$-value is $0.8718$ (whereas $t = 1.32, p \approx 0.19$). Furthermore, line 143 cites the Lp(a) $p$-value as $p = 0.03$, whereas Table 2 reports $p = 0.0031$.

### 3. Biological / Experimental Grounding & Claim Proportionality (STRENGTHS)
* **Strengths:** Routine clinical lipid measurements (HDL, LDL, ApoA1, ApoB, Lp(a), TG) were collected in fasting samples from an angiographically verified cohort.
* **Claim 1 (*PON1* Q192R polymorphism is significantly associated with coronary stenting in the Macedonian population):** `[Methodologically Flawed]` — Derived from post-hoc subgroup dredging on genotyping data that violate Hardy-Weinberg equilibrium at $p = 10^{-12}$, with a contradicted stenting sample size ($n=36$ in Table 1 vs. $n=89$ in Table 5) and a miscalculated 95% CI.
* **Claim 2 (The study analyzes the relationship between PON1 enzyme activity, rs662 genotypes, and CAD risk):** `[Overstated]` — Despite explicitly claiming in the Introduction (line 44) to analyze enzyme activity, PON1 paraoxonase/arylesterase activity was never assayed; the variable `ACT` in Tables 2–3 is Activated Clotting Time (or AST aminotransferase), not PON1 activity.
* **Claim 3 (Lower HDL and ApoA1 and higher Lp(a) in CAD vs. non-CAD):** `[Moderately Supported]` — Biologically expected, though confounded in unadjusted analyses by the large sex imbalance ($75.5\%$ vs. $52.5\%$ male) and statin dosage differences between cases and controls.

### 4. Reproducibility & Data Completeness
* **Bibliography Omission:** Although 46 references are cited in brackets (`[1]`–`[46]`) throughout the text, the `## LITERATURE` section at line 183 is completely empty.
* **Data Availability:** No raw genotype intensity plots or individual patient data are available to audit the TaqMan clustering failure.
</Blinded Review: TIME_ANON_0852>
